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This letter comments a meta-analysis published as
Baker WL, Coleman CI.
Meta-analysis of ascorbic acid for prevention of postoperative atrial fibrillation after cardiac 
surgery.




Baker and Coleman [1] conducted a meta-analysis of 11 studies on ascorbic acid for the prevention 
of postoperative atrial fibrillation (POAF). They concluded that perioperative administration of 
ascorbic acid reduces the frequency of POAF. However, the results of 2 rather large randomized 
controlled trials (RCTs) conducted in the United States were missing from their meta-analysis. 
An RCT of ascorbic acid for POAF is registered with ClinicalTrials.gov, but the results of the study 
have not been published.[2] That RCT’s study chair told me that he and his colleagues did not seek 
publication because their findings were negative (Kramer RS, personal communication, 2016 Mar 
23). He sent me the results of the RCT, which are included in a meta-analysis I subsequently 
conducted (table). 
In a review article, Van Wagoner [6] briefly described an unpublished RCT, conducted by his 
research group, of ascorbic acid for POAF. I contacted Dr. Van Wagoner, who also said that the 
study results were not submitted for publication because they were negative (Van Wagoner DR, 
personal communication, 2015 Sep 26). He sent me the study findings, which also appear in the 
table. 
These instances of publication not being sought because of negative results illustrate publication 
bias. Furthermore, a small trial conducted by Healy et al.,[4] whose results appeared in abstract 
form only, was omitted from Baker and Coleman’s [1] meta-analysis. Baker and Coleman used a 
statistical test to determine whether there might be publication bias in their meta-analysis and stated
that “no significant publication bias was noted (Egger’s p = 0.13).” However, such a theoretical 
calculation does not provide definitive evidence about whether publication bias actually does or 
does not exist. The omission of the aforementioned unpublished studies illustrates that publication 
bias did exist in Baker and Coleman’s meta-analysis and flawed their estimate of the effect of 
ascorbic acid. 
Baker and Coleman stated that “only RCTs that compared ascorbic acid with a placebo or other 
control were included” in their review, but they included the study by Carnes et al. [7] even though 
it was not an RCT. Strangely enough, Baker and Coleman stated that “one study did not involve 
random sequence generation” and referred to the study of Carnes et al., yet that study was included 
in their review. 
To my knowledge, the table herein shows all RCTs involving ascorbic acid that have been 
conducted in the United States. In total, 889 participants were included in these trials, and the 
number of patients with POAF was 268. The three RCTs missing from Baker and Coleman’s meta-
analysis—the first, second, and fourth entries in my table—contribute 680 participants and 203 
cases of POAF, and their combined weight in my meta-analysis is 74.6%. Thus, the majority of 
RCT data from the U.S. trials are missing from the meta-analysis of Baker and Coleman. My meta-
analysis showed a narrow 95% confidence interval (CI) around the null effect. The lower limit of 
that CI indicates that it is unlikely that ascorbic acid reduces the occurrence of POAF by more than 
14%. 
Baker and Coleman’s analysis of 11 studies, 1 of which was not an RCT,[7] yielded an odds ratio of
0.44, indicating that ascorbic acid might decrease the overall frequency of POAF. That calculation 
of average effect is reasonable, but given that the 5 U.S. trials, taken together, showed no benefit 
from ascorbic acid, Baker and Coleman’s results indicate that the benefit occurred in non-U.S. 
trials. Eight of the 11 studies included by Baker and Coleman were conducted outside of the United 
States (mainly in Iran and Greece), and their pooled result indicates a reduction in the risk of POAF 
by 44% (95% CI, 33–53%; p = 10–9). The 95% CIs of the 5 U.S. and the 8 non-U.S. trials are 
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definitely incompatible, which implies that a single estimate of effect cannot be consistent with both
groups of RCTs. 
Panagiotou et al. [8] compared the efficacy of several treatments in less-developed and more-
developed countries and found that, in many cases, the benefits were significantly greater in the 
less-developed countries. Ascorbic acid might have effects on POAF risk in less-developed 
countries but not in more-developed countries. On the basis of the 5 RCTs conducted in the United 
States, there seems to be no justification to conduct further similar trials in the United States, with 
perhaps the exception of studying patients who have particularly low ascorbic acid levels. There is, 
however, strong evidence to encourage further research on ascorbic acid and POAF in less-
developed countries. 
Table. Meta-analysis of U.S. Trials of Ascorbic Acid for Preventing POAF
Ascorbic Acid Group Control Group 






RR (95% CI) 
Donovan et al.[2],a 150 58 154 48 36.0 1.24 (0.91–1.69)
Van Wagoner et al.a 177 44 169 41 31.9 1.02 (0.71–1.48)
Bjordahl et al.[3] 89 27 96 29 21.3 1.00 (0.65–1.56)
Healy et al.[4] 19 5 11 7 6.7 0.41 (0.17–0.99)
Colby et al.[5] 13 4 11 5 4.1 0.68 (0.24–1.92)
Pooled (fixed effect) 448 138 441 130 100 1.04 (0.86–1.27)
The individual relative risk (RR) values and the pooled RR 
were calculated using the RevMan program of the Cochrane collaboration. 
There is no significant heterogeneity among the 5 studies 
(I 2 = 35% and p = 0.18 in the test of heterogeneity). 
POAF = postoperative atrial fibrillation 
CI = confidence interval 
a Data were provided by the investigators and appear here with their permission. 
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